Biotech Values

[rkrw]

RE HGSI, I read over the transcript and have to say I think the deal was a lot better than just OK. Considering this is a drug delivery program, modestly better dosing, not a novel breathrough like drug, $93M upfront (triggered this year), $500M in total milestones, cost split, profit split, probably decent 15-20% royalties ex-US and taken on by nvs, for a drug delivery program into a competitive field is about as good as it gets imo. nvs commitment to hcv is intense. Can't wait to see how they angle into the protease field.